3 results
The objectives of the study are as follows:Primary:• Part 1: To assess the pharmacokinetics and relative bioavailability of three different formulations of PA101 (4% cromolyn sodium with and without mannitol, and 6% cromolyn sodium without mannitol…
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Objectives:The main objective will be to assess whether treatment with nVNS, LXB or both interventions will increase the clearance of Aβ from the brain, compared to pre-treatment, in patients with CAA. Second objective is to study whether CAA…